리젠브리프 · RegenBrief · РегенБриф

Interest in stem cell
and exosome treatments
is growing fast.

RegenBrief tracks the clinical evidence —
trial by trial, indication by indication.

Why regenerative medicine

Aging begins
with changes in
cellular function.

Medicine that repairs damaged tissue
and slows functional decline.
Regenerative medicine validates that promise with clinical evidence.

Cellular regeneration signaling environment

What we cover

Stem cell therapy

Clinical outcomes by indication, safety data, and areas still under investigation.

Research Briefs →

Exosome therapy

Regenerative signaling without cell transplantation. Evidence varies significantly by indication.

Clinical Archive →

Functional longevity

Gait speed, muscle strength, balance — function is the most tangible measure of how we age.
RegenBrief tracks the evidence accumulating in this area alongside regenerative medicine.

Treatment decision checklist

Before you decide on treatment

Indication, clinical evidence,
safety, and regulatory status —
check all of these first.

Get in touch →

Decide carefully.
Get clear information.

RegenBrief helps you make evidence-based choices.

Get in touch →
15
Clinical Archive
6
Research Brief
10
Indications

Research Brief

Regenerative Medicine in 2026: What the Latest Papers Show
From cell therapy to secretome, EVs, and delivery platforms
2026.05.12 Note MSC secretome EV
Brief
Can Stem Cell Therapy Improve Frailty?
From CRATUS and Laromestrocel to Zhu 2024 and Nguyen 2026 — what the MSC frailty trials actually show
2026.05.09 Note MSC frailty anti-aging
Brief
MSC-Derived Exosome Nanoformulations Emerge as Next-Generation Drug Delivery Platform for Targeted Cancer Therapy
Review in International Journal of Pharmaceutics maps biological rationale for delivering chemotherapy, RNA therapeutics, and immunomodulators to tumors / Current evidence is primarily preclinical — standardization, scale-up, and long-term safety remain key hurdles
2026.05.03 Note MSC exosome nanoformulation
Brief
Why Immunogenicity Is the Core Issue in Stem Cell Therapy
Umbilical cord-derived MSCs offer structural advantages in immunogenicity — but the optimal cell source depends on the disease and treatment strategy
2026.04.30 Note MSC immunogenicity umbilical cord
Brief
Exosome Skin Treatments: Growing Promise, Standards Yet to Catch Up
Microneedling combination therapy shows early signals in alopecia, skin aging, and pigmentation — experts say verifying source, manufacturing, quality control, and regulatory standards comes first
2026.04.30 Note exosome dermatology microneedling
Brief
Exosomes Emerge as a New Frontier in Depression Research
A Molecular Psychiatry review proposes exosomes as key mediators linking neuroinflammation, synaptic plasticity, and the gut-brain axis in depression
2026.04.29 Note exosome depression neuroinflammation
Brief

Clinical Archive

View all →
UC-MSC Injection — Umbilical Cord MSC for Interstitial Lung Disease, Phase 1
—
2026.05.12 Clinical PHASE 1UC-MSC
not-yet-recruiting
SECRET-OA — UC-MSC Secretome for Knee Osteoarthritis Pain and Function, Phase 2/3
—
2026.05.12 Clinical PHASE 2 3UC-MSC
not-yet-recruiting
Rincell-1 — Otic Neural Progenitors Combined with Cochlear Implant, First-in-Human Phase 1/2
—
2026.05.12 Clinical PHASE 1 2
not-yet-recruiting
RepCOPDiPS — iPSC-Based Bronchial Epithelial Repair Model for COPD
—
2026.05.12 Clinical NA
recruiting
NSC-EVs — Neural Stem Cell-Derived Exosomes for Early-Onset Alzheimer's Disease, Phase 1
—
2026.05.12 Clinical PHASE 1NSC
not-yet-recruiting
NouvNeu001 — Human Dopaminergic Progenitor Cells for Parkinson's Disease, Phase 1/2
—
2026.05.12 Clinical PHASE 1 2
recruiting
MSC Gel — Mesenchymal Stem Cell Gel for Burn Wound Treatment
—
2026.05.12 Clinical NA
recruiting
hUCMSC-EVs — Umbilical Cord MSC-Derived Extracellular Vesicles for Interstitial Lung Disease, Phase 1
—
2026.05.12 Clinical PHASE 1UC-MSC
not-yet-recruiting

Evidence Notes

Descriptive Statistical Report on Japan's Regenerative Medicine Clinical Practice and Product Development
Analysis of 6,770 provision plans as of March 31, 2026 — 98.8% treatment-purpose, Type III dominant, 16 new PMDA trial notifications
2026.03.31 Note Japan regenerative medicine regenerative medicine safety act
Brief
Statistical Report on Advanced Regenerative Medicine Clinical Research Authorization in South Korea
Analysis of 60 cases as of March 2026 — cell therapy dominant, oncology leads, concentrated in major tertiary hospitals
2026.03.31 Note 첨단재생의료 임상연구 세포치료
Brief